Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Pathkey’s TrialKey Wins Paradigm Contract After Phase 3 Trial Misses Interim Threshold

Pathkey.AI Ltd (PKY) · Information technology

PKY: $0.015 -6.25% · MC: $20M

Pathkey.AI says its TrialKey subsidiary has signed a services agreement with Paradigm Biopharmaceuticals, which is in voluntary administration, to independently assess whether trial design, conduct or analysis could have affected the interim result of Paradigm’s Phase 3 osteoarthritis study; the study did not meet its pre-set threshold to continue, and the outcome remains unchanged. The contract is valued at approximately $25,000 plus GST, and Pathkey says the work turns TrialKey’s broader offering into contracted project work. Internal retrospective testing also showed improved predictive performance, while further capabilities remain under testing or client validation.

Source announcements: 2026-11-10 09:32 to 2026-11-10 09:32 Sydney time
Story updated 2026-11-10 09:42 Sydney time
SourcesPKY Secures Paradigm Contract & Expands Trial Capabilities
Comments